Cargando…

Fesoterodine for the treatment of urinary incontinence and overactive bladder

Overactive bladder (OAB) is a highly prevalent condition, affecting males and females. The prevalence increases with age. Behavioral therapy and antimuscarinic therapy remain the first-line therapies for management of OAB. Despite improvements in symptoms, persistence with antimuscarinic therapy has...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ellsworth, Pamela
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2781061/ https://www.ncbi.nlm.nih.gov/pubmed/19956551

Ejemplares similares

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
por: Wyndaele, Jean-Jacques
Publicado: (2012)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
por: Lee, Raymond T, et al.
Publicado: (2013)

Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder
por: Heesakkers, John, et al.
Publicado: (2022)

Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
por: Morris, Vikky, et al.
Publicado: (2014)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2010)

Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
por: Heesakkers, John, et al.
Publicado: (2017)

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009)

NGF and HB-EGF: Potential Biomarkers that Reflect the Effects of Fesoterodine in Patients with Overactive Bladder Syndrome
por: Kim, Soo Rim, et al.
Publicado: (2015)

Socioeconomic Costs of Overactive Bladder and Stress Urinary Incontinence in Korea
por: Sung, Wooseuk, et al.
Publicado: (2012)

Toileting behaviors, urinary cues, overactive bladder, and urinary incontinence in older women
por: O’Connell, Kathleen A., et al.
Publicado: (2022)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Female Functional Constipation Is Associated with Overactive Bladder Symptoms and Urinary Incontinence
por: Maeda, Takahiro, et al.
Publicado: (2017)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain
por: Peral, Carmen, et al.
Publicado: (2016)

The effect of vitamin D deficiency in children with overactive bladder related urinary incontinence
por: Özçift, Burak, et al.
Publicado: (2022)

Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence
por: Wyman, J F, et al.
Publicado: (2009)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine
por: Wagg, Adrian S., et al.
Publicado: (2021)

The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population
por: Lai, H. Henry, et al.
Publicado: (2016)

The Changes of Voiding Pattern After Midurethral Sling Between Pure Stress Urinary Incontinence and Stress Urinary Incontinence With Overactive Bladder Group
por: Kim, Sun Wook, et al.
Publicado: (2014)

Impact of Transobturator Tape Treatment on Overactive Bladder Symptoms, Particularly Nocturia, in Patients With Mixed Urinary Incontinence
por: Lee, Sang Keun, et al.
Publicado: (2014)

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
por: Campbell, Jonathan D, et al.
Publicado: (2009)

Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence
por: Özkidik, Mete, et al.
Publicado: (2019)

Understanding overactive bladder and urgency incontinence: what does the brain have to do with it?
por: Smith, Ariana L.
Publicado: (2018)

Urinary biomarkers of overactive bladder
por: Tian, Xiao-Jun, et al.
Publicado: (2019)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017)

Sexual Disorders in Women with Overactive Bladder and Urinary Stress Incontinence Compared to Controls: A Prospective Study
por: Naumann, Gert, et al.
Publicado: (2021)

Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy
por: Stahlschmidt, Rebeca, et al.
Publicado: (2020)

Impact of smoking habit on overactive bladder symptoms and incontinence in women
por: Kawahara, Takashi, et al.
Publicado: (2020)

Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo
por: Van Kerrebroeck, Philip EV, et al.
Publicado: (2009)

Association between the Urinary Bladder Volume and the Incidence of “De Novo” Overactive Bladder in Patients with Stress Urinary Incontinence Subjected to Sling Surgeries or Burch Procedure
por: Ciećwież, Sylwester, et al.
Publicado: (2019)

Transcutaneous Temperature Controlled Radiofrequency: Groundbreaking Technology – Female Stress Urinary Incontinence and Overactive Bladder Can Be Treated Noninvasively and with Vulvovaginal Rejuvenation?
por: Mishra, Vineet V., et al.
Publicado: (2023)

Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2014)

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
por: Castro-Diaz, David, et al.
Publicado: (2012)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence
por: Kaaki, Bilal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m0ia4u2p9a0cs8vupu6evng97n